

## OVERVIEW

Catalyst

Summary

## EXECUTIVE SUMMARY

Strategic scoping and focus

Datamonitor key findings

Related reports

## PRODUCT OVERVIEW

Product overview

## MARKETED PRODUCT PROFILES: ANDROGEN BIOSYNTHESIS INHIBITORS

Zytiga (abiraterone acetate; Johnson & Johnson)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

## MARKETED PRODUCT PROFILES: IMMUNOTHERAPIES

Provenge (Sipuleucel-T; Dendreon/Kyowa Hakko Kirin/Immune Response)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

## MARKETED PRODUCT PROFILES: CYTOTOXICS

Jevtana (cabazitaxel; Sanofi)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Taxotere (docetaxel; Sanofi)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

## MARKETED PRODUCT PROFILES: GNRH ANALOGS

Lupron (leuprolide acetate; Takeda/Abbott)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

## MARKETED PRODUCT PROFILES: ANTI-ANDROGENS

Casodex (bicalutamide; AstraZeneca)

Drug profile

- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness

Nilandron (nilutamide; Sanofi/Astellas)

- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness

Eulexin (flutamide; Merck & Co. /Nippon Kayaku)

- Drug profile
- Development overview
- SWOT analysis
- Product positioning
- Clinical and commercial attractiveness

#### PIPELINE PRODUCT PROFILES

Avastin (bevacizumab; Genentech/Roche/Chugai)

- Drug profile
- Development overview
- Clinical and commercial attractiveness

DCVax-prostate (Northwest Biotherapeutics)

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

MDV3100 (Medivation/Astellas)

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness
- Datamonitor drug assessment summary for MDV3100

Orteronel (TAK-700; Takeda)

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

Revlimid (lenalidomide; Celgene)

- Drug profile
- Development overview
- SWOT analysis
- Satisfaction of unmet needs
- Clinical and commercial attractiveness

Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka)  
Drug profile  
Development overview  
SWOT analysis  
Satisfaction of unmet needs  
Clinical and commercial attractiveness

TASQ (tasquinimod; Active Biotech/Ipsen)  
Drug profile  
Development overview  
SWOT analysis  
Satisfaction of unmet needs  
Clinical and commercial attractiveness

Yervoy (ipilimumab; Medarex/Bristol-Myers Squibb)  
Drug profile  
Development overview  
SWOT analysis  
Satisfaction of unmet needs  
Clinical and commercial attractiveness

Zaltrap (aflibercept/VEGF-Trap; Regeneron/Sanofi)  
Drug Profile  
Development overview  
SWOT analysis  
Satisfaction of unmet needs  
Clinical and commercial attractiveness

Zibotentan (ZD-4054; AstraZeneca)  
Drug profile  
Development overview  
SWOT analysis  
Satisfaction of unmet needs  
Clinical and commercial attractiveness

## BIBLIOGRAPHY

Journal papers  
Websites  
Datamonitor reports  
Other

## APPENDIX

Market definition  
PharmaVitae Explorer database  
Contributing experts  
Conferences attended  
Report methodology

## TABLES

Table: Key marketed products for prostate cancer, 2011  
Table: Key pipeline products for prostate cancer, 2011  
Table: Zytiga ó drug profile , 2011  
Table: Pivotal clinical trial summary for Zytiga in prostate cancer, 2011

Table: Datamonitor's drug assessment summary of Zytiga for prostate cancer, 2011  
Table: Provenge ó drug profile, 2011  
Table: Overview of pivotal trial data for Provenge in prostate cancer  
Table: Datamonitor's drug assessment summary of Provenge (sipuleucel-T; Dendreon/Kyowa Hakko Kirin/Immune Response) for prostate cancer, 2011  
Table: Jevtana ó drug profile, 2011  
Table: Overview of TROPIC trial data for Jevtana in prostate cancer, 2011  
Table: Datamonitor's drug assessment summary of Jevtana (cabazitaxel; Sanofi) for prostate cancer, 2011  
Table: Taxotere ó drug profile, 2011  
Table: Overview of SWOG 9916 and TAX 327 trials of Taxotere in CRPC  
Table: Datamonitor's drug assessment summary of Taxotere (docetaxel; Sanofi) for prostate cancer, 2011  
Table: Lupron ó drug profile, 2010  
Table: Overview of pivotal trial data for Lupron depot 3 month 40mg  
Table: Datamonitor's drug assessment summary of Lupron (leuprolide acetate; Takeda/Astellas) for prostate cancer, 2011  
Table: Casodex ó drug profile, 2011  
Table: Overview of pivotal trial data for Casodex in prostate cancer  
Table: Datamonitor's drug assessment summary of Casodex (bicalutamide; AstraZeneca) for prostate cancer, 2011  
Table: Main factors impacting on Casodex revenue  
Table: Nilandron ó drug profile, 2011  
Table: Overview of pivotal trial data for Nilandron in prostate cancer  
Table: Datamonitor's drug assessment summary of Nilandron (nilutamide; Sanofi/Astellas) for prostate cancer, 2011  
Table: Eulexin ó drug profile, 2011  
Table: Overview of pivotal trial data for Eulexin in prostate cancer  
Table: Datamonitor's drug assessment summary of Nilandron (flutamide; Merck & Co./Nippon Kayaku) for prostate cancer, 2011  
Table: Avastin ó drug profile , 2011  
Table: Clinical trial summary for Avastin in prostate cancer, 2011  
Table: CALGB 90401 trial design for Avastin in metastatic, castrate-resistant prostate cancer patients  
Table: CALGB 90401 trial results for Avastin in metastatic, castrate-resistant prostate cancer patients  
Table: Docetaxel versus docetaxel plus Avastin in progressive castrate-resistant prostate cancer following first-line docetaxel  
Table: DCVax-prostate ó drug profile , 2011  
Table: Clinical trial summary for DCVax-prostate in prostate cancer, 2011  
Table: DCVax-prostate versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer  
Table: MDV3100 ó drug profile, 2011  
Table: Clinical trial summary for MDV3100 in prostate cancer, 2011  
Table: Pivotal Phase III PREVAIL and AFFIRM trials for MDV3100 in prostate cancer

Table: Long-term follow up results for MDV3100 in advanced prostate cancer

Table: MDV3100 versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer

Table: Datamonitor drug assessment summary of MDV3100 (Medivation/Astellas) for prostate cancer, 2011

Table: Orteronel ó drug profile, 2011

Table: Clinical trial summary for Orteronel in prostate cancer, 2011

Table: Orteronel versus second-line comparator therapy carboplatin for the treatment of metastatic castrate-resistant prostate cancer after docetaxel failure

Table: Datamonitor drug assessment summary of Orteronel (TAK-700; Takeda) for prostate cancer, 2011

Table: Revlimid ó drug profile, 2010

Table: Clinical trial summary for Revlimid in prostate cancer, 2011

Table: Revlimid versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer

Table: Datamonitor drug assessment summary of Revlimid (lenalidomide; Celgene) for prostate cancer, 2011

Table: Sprycel ó drug profile , 2011

Table: Clinical trial summary for Sprycel (dasatinib) in prostate cancer, 2011

Table: Sprycel versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer

Table: Datamonitor drug assessment summary of Sprycel (dasatinib; Bristol-Myers Squibb) for prostate cancer, 2011

Table: TASQó drug profile, 2011

Table: Clinical trial summary for TASQ in prostate cancer, 2011

Table: TASQ versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer

Table: Datamonitor drug assessment summary of TASQ (tasquinimod; Active Biotech/Ipsen) for prostate cancer, 2011

Table: Yervoy ó drug profile, 2011

Table: Clinical trial summary for Yervoy in prostate cancer, 2011

Table: Yervoy versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer

Table: Datamonitor drug assessment summary of Yervoy (ipilimumab; Medarex/Bristol-Myers Squibb) for prostate cancer, 2011

Table: Zaltrap ó drug profile, 2011

Table: VENICE trial to evaluate Zaltrap in prostate cancer, 2011

Table: Zaltrap versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer

Table: Datamonitor drug assessment summary of Zaltrap (aflibercept/VEGF Trap; BTG/Johnson & Johnson) for prostate cancer, 2011

Table: Zibotentan ó drug profile, 2009

Table: Clinical trial summary for Zibotentan in prostate cancer, 2011

Table: Zibotentan versus first-line comparator therapy docetaxel (plus prednisone) for the treatment of metastatic castrate-resistant prostate cancer

Table: Summary of therapeutic classes in prostate cancer by ATC code, 2011

## FIGURES

- Figure: Zytiga ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Zytiga for prostate cancer, 2011
- Figure: Provenge ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Provenge (sipuleucel-T; Dendreon/Kyowa Hakko Kirin/Immune Response) for prostate cancer, 2011
- Figure: Jevtana ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Jevtana (cabazitaxel; Sanofi) for prostate cancer, 2011
- Figure: Taxotere ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Taxotere (docetaxel; Sanofi) for prostate cancer, 2011
- Figure: Lupron ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Lupron (leuprolide acetate; Takeda/Astellas) for prostate cancer, 2011
- Figure: Casodex ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Casodex (bicalutamide; AstraZeneca) for prostate cancer, 2011
- Figure: Nilandron ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Nilandron (nilutamide; Sanofi/Astellas) for prostate cancer, 2011
- Figure: Eulexin ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor's drug assessment summary of Eulexin (flutamide; Merck & Co./Nippon Kayaku) for prostate cancer, 2011
- Figure: Phase II results investigating neoadjuvant docetaxel and Avastin in high-risk localized prostate cancer
- Figure: DCVax-prostate ó SWOT analysis in prostate cancer, 2011
- Figure: Phase I/II study of MDV3100 in castrate-resistant prostate cancer
- Figure: MDV3100 ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor drug assessment summary of MDV3100 (Medivation/Astellas) for prostate cancer, 2011
- Figure: Orteronel ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor drug assessment summary of Orteronel (TAK-700; Takeda) for prostate cancer, 2011
- Figure: Results of a Phase II double-blind, randomized study of Revlimid in non-metastatic castrate-resistant prostate cancer
- Figure: Revlimid ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor drug assessment summary of Revlimid (lenalidomide; Celgene) for prostate cancer, 2011
- Figure: Phase II results for patients with metastatic CRPC with rising PSA levels
- Figure: Phase I/II results investigating first-/second-line Sprycel and docetaxel in metastatic castrate-resistant prostate cancer
- Figure: Sprycel ó SWOT analysis in prostate cancer, 2011
- Figure: Datamonitor drug assessment summary of Sprycel (dasatinib; Bristol-Myers Squibb/Otsuka) for prostate cancer, 2011
- Figure: TASQ ó SWOT analysis in prostate cancer, 2011

Figure: Datamonitor drug assessment summary of TASQ (tasquinimod; Active Biotech/Ipsen) for prostate cancer, 2011

Figure: Phase I/II study investigating first/second-line Yervoy alone and in combination with radiotherapy in metastatic castrate-resistant prostate cancer

Figure: Phase II study investigating Yervoy either as a monotherapy or in combination with docetaxel for castrate-resistant prostate cancer

Figure: Yervoy ó SWOT analysis in prostate cancer, 2011

Figure: Datamonitor drug assessment summary of Yervoy (ipilimumab; Medarex/Bristol-Myers Squibb) for prostate cancer, 2011

Figure: Zaltrap ó SWOT analysis in prostate cancer, 2009

Figure: Datamonitor drug assessment summary for Zaltrap (aflibercept/VEGF-Trap; Regeneron/Sanofi) in prostate cancer, 2011

Figure: Phase II study investigating first-line Zibotentan in castrate-resistant prostate cancer with bone metastases

Figure: The PharmaVitae Explorer